Skip to main content

Advertisement

Fig. 4 | BMC Cancer

Fig. 4

From: Binimetinib inhibits MEK and is effective against neuroblastoma tumor cells with low NF1 expression

Fig. 4

Outcomes of patients with neuroblastoma based on MEK1 and NF1 gene expression. The NCI Oncogenomics gene expression databases were evaluated for outcomes of patients with neuroblastoma and Kaplan-Meier survival curves were generated. a Estimated overall survival for patients who have tumors with high NF1 gene expression (n = 177; gray) and low NF1 gene expression (n = 176; black) (log-rank test; p = 1.88e-11). b Estimated overall survival for patients with stage 4 neuroblastoma who have high (n = 35; black) and low (n = 90; dashed black) NF1 gene expression and for patients with tumors of all other stages with high (n = 142; gray) and low (n = 86; dashed gray) NF1 gene expression. c Estimated overall survival for patients who have tumors with high MEK1 gene expression (n = 154; gray) and low MEK1 gene expression (n = 153; black) (log-rank test; p = 0.44). d Estimated overall survival for patients with stage 4 neuroblastoma who have high (n = 44; black) and low (n = 54; dashed black) MEK1 gene expression and for patients with tumors of all other stages with high (n = 110; gray) and low (n = 99; dashed gray) MEK1 gene expression

Back to article page